PENTIXAPHARM HOLDING N AG - Asset Resilience Ratio
PENTIXAPHARM HOLDING N AG (PTP) has an Asset Resilience Ratio of 0.82% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PENTIXAPHARM HOLDING N AG current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how PENTIXAPHARM HOLDING N AG's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PTP current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down PENTIXAPHARM HOLDING N AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read PENTIXAPHARM HOLDING N AG (PTP) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €342.00K | 0.82% |
| Total Liquid Assets | €342.00K | 0.82% |
Asset Resilience Insights
- Limited Liquidity: PENTIXAPHARM HOLDING N AG maintains only 0.82% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
PENTIXAPHARM HOLDING N AG Industry Peers by Asset Resilience Ratio
Compare PENTIXAPHARM HOLDING N AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for PENTIXAPHARM HOLDING N AG (2023–2025)
The table below shows the annual Asset Resilience Ratio data for PENTIXAPHARM HOLDING N AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.82% | €342.00K ≈ $399.83K |
€41.86 Million ≈ $48.94 Million |
+0.09pp |
| 2023-12-31 | 0.72% | €531.00K ≈ $620.79K |
€73.40 Million ≈ $85.81 Million |
-- |
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorde… Read more